FOSTERING INVESTMENT IN THE DEVELOPMENT OF NEW ANTIBACTERIAL TREATMENTS

23 Oct 2018
14:30-17:30
Room XXV

FOSTERING INVESTMENT IN THE DEVELOPMENT OF NEW ANTIBACTERIAL TREATMENTS

Antimicrobial resistant infections (AMR) are on the rise and pose a significant global risk. Developing countries, in particular, are vulnerable because they often lack key medical resources. The development of new antibacterial treatments is costly while the return on investment is low. Organized in cooperation with the World Health Organization (WHO), the conference will explore solutions to this dilemma, seeking to facilitate cooperation between biotech firms, potential investors and governments for AMR investment. It will present some innovative technologies that need financial support and provide a matchmaking platform to connect impact investors with researchers and developers of treatments against AMR.

Issues for the debate:

  • What is the role of governments?
  • What are the needs of the industry?
  • Which innovative means of investment can help address the AMR problem?

In partnership with:

Event Manager: Mr. Christoph Spennemann
Contact email: christoph.spennemann@unctad.org

Dr. Yoshinori Yamano

Chief Scientific Officer for Infectious Diseases Pharmaceutical Research Division SHIONOGI & CO., LTD.

Dr. Rich Lawson

CARB-X Senior Project Manager, Boston University School of Law

Professor Laura Piddock

Head of Scientific Affairs, Global Antibiotic Research and Development Partnership (GARDP)

Dr. Andreas Sandgren

Policy Advisor, ReAct – Action on Antibiotic Resistance Uppsala University, Sweden

Dr. Clemens Martin Auer

Director-General, Federal Ministry of Labour, Social Affairs, Health and Consumer Protection, Austria

Mr. Tomotaka Goji

Managing Partner, The University of Tokyo Edge Capital Japan Fund

Dr. Niresh Bhagwandin

Executive Manager of Strategic Research Initiatives, South Africa Medical Research Council

Mr. Kees de Joncheere

Chairman, Netherlands Antibiotic Development Platform

Mr. Christopher Egerton-Warburton

Expert Advisory Board Chair, United Kingdom Global AMR Innovation Fund

Dr. Anand Anandkumar

CEO, Bugworks Research

Dr. Marc Gitzinger

CEO, Bioversys

Ms. Jenny Hellman

Public Health Agency of Sweden

Dr. Ranieri Guerra

Assistant Director General for Special Initiatives, World Health Organisation

Mr. Virander Paul

Ambassador/Deputy Permanent Representative of India to the UN